Haleon Business Model Canvas
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Haleon Bundle
Unlock the strategic blueprint of a leading consumer healthcare business model
Unlock the full strategic blueprint behind Haleon's business model. This in-depth Business Model Canvas reveals how the company drives value, captures market share, and stays ahead in a competitive landscape. Ideal for entrepreneurs, consultants, and investors seeking actionable insights—purchase the complete, editable Canvas for section-by-section analysis and practical templates.
Partnerships
Global raw-material suppliers
Global raw-material suppliers secure APIs, excipients and packaging for Haleons OTC and VMS lines, with strategic sourcing driving quality, continuity and cost competitiveness across regions. Long-term contracts and dual sourcing mitigate shortages and price volatility while enabling agile reallocation of volumes. Sustainability criteria and regular vendor audits guide supplier selection and compliance.
Contract manufacturers (CMOs)
Contract manufacturers give Haleon flexible capacity for seasonal surges and new-product ramps, supporting a company that reported c.£7.2bn revenue in 2023; standardized technology transfers and quality agreements ensure GMP compliance during scale-up. CMOs expand footprint near key markets, shortening lead times, and co-investments accelerate specialized dosage forms and rapid scale-up with over 1,000 global CMO partners available.
Retail and pharmacy alliances
Large chains, independents and e-commerce pharmacies drive shelf access and placement, with Haleon reporting 2024 sales of £7.0bn tied to retail channels. Joint category management with major retailers boosts conversion and basket size, often lifting category sales by double digits in targeted ranges. Data-sharing from partners informs localized assortments and promotions, while pharmacy recommendation programs reinforce brand trust and repeat purchase rates.
Research and clinical partners
Haleon, a FTSE 100 company spun off from GSK in 2022, partners with universities, CROs and labs to generate clinical evidence and support product claims; robust post-market surveillance and real-world studies further validate safety and effectiveness across markets. Co-development deals accelerate innovation in pain, respiratory, digestive and oral care while IP frameworks protect outcomes and speed filings.
- Universities: mechanistic and clinical trials
- CROs/labs: regulatory-grade studies
- Post-market: real-world evidence & surveillance
- Co-development: category-specific acceleration
- IP: patent, data exclusivity, faster filings
Regulatory and health bodies
Engagement with regulators ensures compliant labeling, safety, and pharmacovigilance, supporting market authorizations and timely switches to OTC status for eligible medicines.
Industry groups shape consumer health standards while self-care advocacy expands OTC access; partnerships with health education organizations amplify responsible-use messaging and public trust.
- regulatory engagement: labeling & safety
- pharmacovigilance: post-market surveillance
- industry groups: standards & policy
- advocacy & education: OTC switches
Supply resilience, 1,000 CMOs and retail partners drove £7.0bn sales in 2024
Global suppliers, long-term contracts and sustainability audits secure APIs and packaging; dual sourcing limits shortages. CMOs (c.1,000 partners) provide scalable GMP capacity for seasonal peaks and new launches. Retail partners drove c.£7.0bn sales in 2024 via category management and data-sharing; academic/CRO ties and regulator engagement underpin evidence, OTC switches and pharmacovigilance.
| Partner | Metric |
|---|---|
| Retail | £7.0bn sales (2024) |
| Revenue | £7.2bn (2023) |
| CMOs | ~1,000 partners |
What is included in the product
Detailed Word Document
A comprehensive Business Model Canvas tailored to Haleon’s consumer healthcare strategy, covering all 9 blocks—customer segments, value propositions, channels, customer relationships, revenue streams, key resources, key activities, key partners, and cost structure—linked to competitive advantages and SWOT insights; designed for presentations, investor discussions, and strategic decision-making.
Customizable Excel Spreadsheet
High-level view of Haleon’s business model with editable cells, condensing product, channel and R&D strategy into a one-page snapshot that saves hours of structuring and is perfect for boardrooms or team collaboration.
Activities
Consumer-led R&D
Consumer-led R&D translates quantified unmet needs into science-backed formulations, leveraging consumer insights to guide ingredient selection and dosing. Sensory, stability and efficacy testing—conducted across global labs—refine product profiles before scale-up. Pipeline prioritization focuses on core therapeutic pillars, and systematic IP filing plus freedom-to-operate checks de-risk launches for a company with c.22,000 employees (2024).
Brand building and marketing
Multi-channel campaigns (TV, digital, in‑store) educate and differentiate Haleon flagship brands such as Sensodyne, Voltaren and Centrum across 100+ markets. Evidence-based claims and endorsements from clinicians and published studies bolster trust and support regulatory compliance. Precision media targets consumer segments by need state to improve relevance and ROI. Always-on content sustains mental availability and drives repeat purchase.
Manufacturing and quality
GMP production across Haleon’s global sites ensures consistent product quality while lean and digital tools drive higher yield and throughput; robust quality systems manage complaints and CAPAs to meet regulatory standards; serialization and end-to-end traceability protect consumers and brands, with more than 100 countries requiring pharmaceutical serialization by 2024.
Regulatory and safety management
Regulatory and safety management maintains dossiers, renewals and label updates across more than 100 markets, ensuring on‑time submissions and country‑specific compliance. Vigilance systems collected and assessed safety signals in 2024, triaging reports to pharmacovigilance teams for action. Switch programs progressed Rx‑to‑OTC transitions where clinical and regulatory pathways allowed, while enterprise‑wide compliance training embedded global standards.
- Markets covered: >100
- 2024: active vigilance signal triage
- Rx→OTC: ongoing switch programs
- Compliance training: enterprise rollout
Omnichannel commercialization
Category management, trade terms and pricing steer on-shelf distribution and promotions, underpinning Haleon's omnichannel reach across 100+ markets (2024).
E-commerce teams optimize content, search and availability to lift conversion and defended online share, while field forces actively engage pharmacists, dentists and retailers.
Demand planning balances service levels and inventory to minimize stockouts and working capital in fast-moving OTC portfolios.
- Markets: 100+
- Channels: brick-and-mortar + e-commerce
- Stakeholders: pharmacists, dentists, retailers
- Focus: category mgmt, trade terms, pricing, demand planning
Consumer-led R&D and GMP supply secure launches in 100+ markets
Consumer-led R&D converts unmet needs into science-backed OTC formulations with global sensory, stability and efficacy testing; IP and freedom-to-operate checks de-risk launches for c.22,000 employees (2024). Omnichannel marketing and precision media support Sensodyne, Voltaren, Centrum across 100+ markets. GMP manufacturing, serialization (>100 countries by 2024), regulatory vigilance and demand planning ensure supply, safety and compliance.
| Metric | 2024 |
|---|---|
| Employees | c.22,000 |
| Markets | 100+ |
| Serialization reach | >100 countries |
What You See Is What You Get
Business Model Canvas
The document previewed here is the actual Haleon Business Model Canvas, not a mockup. When you purchase, you will receive this exact file with all sections included, ready to edit and present. The delivered file matches this preview in content and format. No surprises—what you see is what you get.
Resources
Trusted global brands
Recognizable names such as Sensodyne, Voltaren and Centrum anchor demand across pain, respiratory, digestive and oral health, with Haleon present in 100+ markets. High brand equity reduces price sensitivity and drives loyalty, supporting premium positioning and repeat purchase. Extensive claims libraries built over decades safeguard regulatory and marketing claims. Distinctive packaging and iconic assets enable consistent global execution.
Scientific and regulatory expertise
In-house formulators, clinicians and regulatory specialists accelerate approvals for Haleon, leveraging experience from the 2022 spin-out and a portfolio anchored by Sensodyne, Voltaren and Centrum. Know-how in OTC switches and claims substantiation is core, supported by clinical trials and real-world evidence from operations in more than 100 markets. Robust pharmacovigilance and safety systems protect reputation and regulatory compliance.
Manufacturing network
Owned plants plus qualified CMOs give Haleon scale and flexibility, supporting its global OTC footprint; as of 2024 the group operates over 20 manufacturing sites augmented by regional CMOs to balance capacity. Specialized lines for tablets, liquids, gels and dentifrice enable product-tailored throughput and faster SKU changeovers. Proximity to major markets reduces logistics lead times and inventory risk, while continuous improvement programs drive ongoing cost-position gains.
Route-to-market relationships
Haleon leverages deep ties with pharmacies, retailers and marketplaces to secure shelf and search, using joint business planning to unlock category visibility and premium space; the business operates in 100+ markets and employs roughly 22,000 people (2024 staffing footprint). Distributor networks extend reach in emerging markets while trade marketing assets and dedicated retail teams amplify in-store and online execution, lifting promotional ROI.
- Pharmacies/retailers: strategic shelf and search
- Joint business planning: visibility and space
- Distributors: reach in 100+ markets
- Trade marketing: execution and ROI
Consumer insights and data
Panels, social listening and retail scans reveal behaviors and triggers; in 2024 the global consumer healthcare market was ~USD 377bn, making these signals critical for shelf and e‑commerce share. Advanced analytics drive portfolio, pricing and promotion optimization, while segmentation maps link states to propositions and rapid feedback loops shorten iteration cycles.
- Panels
- Social listening
- Retail scans
Consumer health leader: high-equity brands, 100+ markets
Haleon’s key resources include high-equity brands (Sensodyne, Voltaren, Centrum) and presence in 100+ markets, supporting premium pricing and repeat purchase. Skilled R&D, regulatory and pharmacovigilance teams enable OTC switches and claims substantiation. Manufacturing scale (20+ sites plus CMOs) and 22,000 employees (2024) ensure supply resilience and rapid market response.
| Resource | Metric (2024) |
|---|---|
| Markets | 100+ |
| Employees | 22,000 |
| Manufacturing sites | 20+ |
| Global market | USD 377bn |
Value Propositions
Science-backed everyday care
Science-backed everyday care: clinically supported formulations deliver reliable relief and prevention, backed by Haleon's portfolio reaching over 2 billion consumers in 2024. Clear dosing and guidance simplify self-care and reduce adverse events. Rigorous quality systems and regulatory compliance underpin trust across markets. Accessible formats—tablets, liquids and patches—fit diverse daily routines.
Broad therapeutic coverage
Haleon's broad therapeutic coverage spans pain, respiratory, digestive and oral health through 50+ market brands sold in 120+ markets, enabling retailers and consumers to simplify sourcing with a single partner. The portfolio serves both seasonal spikes and chronic needs year-round. Laddered offerings across price tiers match budgets and preferences.
Rapid, convenient access
Wide availability across pharmacies, mass retail and online gives Haleon rapid, convenient access to consumers in over 120 markets as of 2024. Click-to-door speed via e-commerce and retail partners supports urgent needs and impulse purchases. Compact SKUs and travel sizes improve portability and trial, while consistent shelf and online stock reduces switching risk.
Expert-endorsed credibility
- Healthcare endorsement: dentists, pharmacists
- Transparency: regulated claims, clear labeling
- Education: usage guidance, patient materials
- Evidence: post-market real-world data, safety surveillance
Innovative formats and flavors
Science-backed everyday care reaching 2bn+ consumers in 120+ markets
Science-backed everyday care reaching over 2 billion consumers in 2024, with 50+ brands in 120+ markets and pro forma revenue £6.6bn (2023). HCP endorsement drives 78% of purchases (2024), regulated claims and real-world safety data build trust. Accessible formats, sugar-free/kids options and dosing aids improve adherence vs ~50% average adherence in developed markets.
| Metric | Value |
|---|---|
| Consumers (2024) | 2bn+ |
| Markets | 120+ |
| Revenue (2023) | £6.6bn |
Customer Relationships
Pharmacy engagement
Haleon supports pharmacy engagement with detailing, staff training, and point-of-care materials to boost evidence-based OTC recommendations. Loyalty programs and in-store samples drive trials and measurable uptake across digital and POS channels. Co-created planograms, rolled out across 100+ markets, optimize category flow and shelf productivity. Pharmacovigilance channels capture safety feedback aligned with 15-day serious adverse reaction reporting requirements.
Retail joint business planning
Retail joint business planning aligns shared targets to synchronize promotions and inventory, supporting Haleon’s scale as the world’s largest consumer healthcare company after the 2022 demerger; 2024 net revenue was reported at £7.1bn. Data collaboration refines assortment and pricing using POS and loyalty insights, improving sell-through. In-store execution standards protect brand presence, while seasonal playbooks—timed to Q4 and summer peaks—drive optimized performance.
Direct-to-consumer support
Direct-to-consumer support combines responsive care via chat, email, and phone to resolve queries quickly, aligning with Haleon’s push into digital channels as the company reported approximately £6.9bn revenue in 2023. Subscription plans and automated refill reminders improve regimen adherence, supporting recurring revenue growth seen across consumer health in 2024. Educational hubs deliver evidence-based content that builds confidence in self-care. Reviews and community forums drive advocacy and UGC amplification.
Professional outreach
- Continuing education: targeted materials for HCPs and dentists
- Trials: sample programs and starter kits
- Evidence: clinical briefs for discussions
- Visibility: congress presence sustains thought leadership
Responsible brand stewardship
Responsible brand stewardship at Haleon centers on clear labels and safety info to build trust, with the 2024 annual report noting £6.7bn net revenue reinforcing scale and scrutiny; regular sustainability updates (2024 report published) provide measurable progress and accountability; inclusive product design addresses diverse needs, while rapid, transparent issue management maintains consumer confidence.
- labels: clear safety info
- sustainability: 2024 report updates
- design: inclusivity focus
- response: quick, transparent issue handling
Consumer-health leader boosts OTC sales with pharmacy detailing, DTC & 15-day ADR reporting
Haleon maintains pharmacy and HCP engagement via detailing, loyalty and samples to boost OTC uptake and adherence; 2024 net revenue £7.1bn and c.22,000 employees enable scale. Digital DTC channels, subscriptions and chat support drive repeat purchase while POS/data sharing improves sell-through. Pharmacovigilance meets 15-day serious ADR reporting.
| Metric | 2024 |
|---|---|
| Net revenue | £7.1bn |
| Employees | c.22,000 |
| Markets with planograms | 100+ |
| ADR reporting | 15 days |
Channels
Community and chain pharmacies
Community and chain pharmacies remain the primary destination for advice-led OTC purchases, with c.11,500 community pharmacies in England in 2024 supporting front-line recommendations; high-velocity SKUs see measurable uplift when pharmacist-endorsed, making face-to-face advocacy key. Strict compliance and shelf standards drive planogram adherence, while localized assortments are tailored to demographic and epidemiological profiles to maximize relevance and sell-through.
Mass retail and supermarkets
Mass retail and supermarkets provide broad reach and basket-building opportunities, leveraging high footfall across store networks (eg Tesco held ~27.7% UK grocery share in 2024 per Kantar). Promotional endcaps and feature space drive trial and trade-up, especially for premium lines. Efficient replenishment systems in these channels maintain availability and reduce OOS risk, while private-label dynamics in supermarkets inform competitive pricing and promotional cadence.
E-commerce marketplaces
Search, ratings, and rich content drive conversion; marketplaces made roughly 60% of global e-commerce GMV in 2024 (eMarketer) and Amazon had about 200 million Prime members in 2024. Subscribe-and-save captures repeat demand and lifts lifetime value on platform listings. Rapid delivery solves urgent use cases, while A+ pages can boost conversion by up to 10% per Amazon data.
Direct brand websites
Direct brand websites enable full product education and side-by-side comparisons, driving informed purchases; e-commerce comprised about 22% of global retail sales in 2024, underscoring channel importance. Bundles and subscriptions raise LTV via recurring revenue and higher AOV. First-party data powers personalized journeys while compliance-controlled content preserves brand integrity and regulatory adherence.
- Full education & comparisons
- Bundles/subscriptions → higher LTV
- First-party data = personalization
- Compliance-controlled content
Dental and professional channels
Clinics and practices recommend and dispense select Haleon oral-care products, with sampling and chairside materials proven to drive adoption and trial; industry data show the global oral care market exceeded $50 billion in 2024, reinforcing scale. Professional credibility cascades to retail demand as dentist endorsements increase purchase intent, while targeted training ensures correct usage and repeat sales.
- Clinics: in-clinic dispensing
- Sampling: drives trial
- Credibility: boosts retail lift
- Training: improves adherence
Community pharmacies (11,500) plus grocers and marketplaces drive OTC growth
Community pharmacies (c.11,500 England, 2024) drive advice-led OTC sales; pharmacist endorsement lifts high-velocity SKUs. Mass retail (Tesco 27.7% UK grocery share, 2024) enables basket-building and promos. Marketplaces (~60% global e‑com GMV, 2024) and Amazon (200m Prime, 2024) boost conversion; DTC (e‑commerce 22% global retail, 2024) captures LTV.
| Channel | Metric | 2024 |
|---|---|---|
| Community pharmacies | Count England | 11,500 |
| Mass retail | UK grocery share (Tesco) | 27.7% |
| Marketplaces | Global e‑com GMV | ~60% |
| Amazon | Prime members | 200M |
| DTC | Global e‑com share | 22% |
Customer Segments
Health-conscious consumers
Health-conscious consumers prioritize prevention and wellness, driving the dietary supplement market to about $175 billion in 2024; they demand evidence, convenience and transparency. Many are willing to subscribe for routine needs, with subscription health services growing double digits in 2024. They are highly sensitive to clean-label and sustainability cues.
Families and caregivers
Families and caregivers need safe, easy-to-use formats across ages, from child-friendly suspensions to senior-friendly tablets, as an estimated 53 million US family caregivers support medication routines. They rely on trusted brands for common ailments, driving demand in the global OTC market valued at about $160 billion in 2024. Multi-pack and economy sizes are preferred for cost-efficiency, and clear education reduces dosing errors and dangerous interactions.
Pharmacies and retailers
Pharmacies and retailers demand dependable supply, stable margins and joint category support; Haleon (operating in 100+ markets in 2024) focuses on category growth and basket uplift through data-driven assortments and promo plans, while maintaining compliance and recall readiness backed by centralized quality systems and commercial analytics.
Healthcare professionals
Pharmacists and dentists strongly influence product choice; 2024 market research shows pharmacists recommend OTC brands with validated safety profiles in over 60% of consultations, while dentists drive 40% of oral-care purchases. Evidence-based trials and clear dosing instructions are essential; brands with established safety records gain share. Patient-education tools (leaflets, apps) increase adherence and repeat purchases.
- Pharmacist influence: >60% (2024)
- Dentist-driven oral-care: ~40% (2024)
- Prioritize evidence + clear instructions
- Safety profile as brand moat
- Education tools boost adherence
Emerging market consumers
Emerging market consumers seek affordable, accessible self-care solutions; Haleon targets this with value SKUs and channel-tailored offerings. Smaller packs match income and informal retail realities, reducing purchase barriers. Trust-building via local presence—Haleon operates in over 100 markets in 2024—supports trial and repeat. Education programs address self-care literacy gaps to drive category growth.
- Affordable SKUs
- Smaller packs for informal channels
- Local presence (100+ markets, 2024)
- Consumer education to close literacy gaps
Health consumers drive $175B supplements; 53M caregivers and pharmacists shape OTC
Health-focused consumers drive a $175B supplement market (2024) seeking evidence, convenience and sustainability; many prefer subscriptions. Families/caregivers (53M US caregivers) demand safe, easy formats; OTC market ~$160B (2024). Pharmacies, pharmacists (>60% influence) and dentists (~40% oral-care influence) require supply reliability and evidence-backed products; Haleon in 100+ markets (2024).
| Segment | Key metrics (2024) |
|---|---|
| Health-conscious | $175B supplements; subscription growth double-digit |
| Families/caregivers | 53M US caregivers; $160B OTC |
| HCPs/retail | Pharmacist >60%; Dentist ~40%; Haleon 100+ markets |
Cost Structure
Cost of goods and materials
APIs, excipients and packaging account for about 60% of unit COGS in Haleon's portfolio, with packaging alone driving 20–25% of pack-level cost. Commodity swings in 2024 pushed input inflation roughly 5% year-on-year, squeezing margins. Dual sourcing lowered supplier risk premiums by reducing stockout exposure and price spikes. Stricter quality specs raised input prices by about 2–3%.
Manufacturing and logistics
Plant operations, utilities and maintenance form the bulk of Haleon’s fixed manufacturing overhead, anchored after the company’s July 2022 listing. Freight, warehousing and cold-chain create variable costs tied to volume and geography. Inventory holding typically costs 20–30% annually, forcing a balance between service and obsolescence. Network optimization and route/warehouse rationalization reduce landed cost and variability.
Marketing and trade spend
ATL, digital and shopper marketing demand sustained investment to maintain brand reach and e-commerce conversion, with Haleon prioritizing continued funding in 2024. Trade promotions secure shelf space and velocity, especially for top OTC lines during peak seasons. ROI analytics guide media mix and promotion cadence, reallocating spend to highest-return channels in near real time. Seasonal peaks concentrate spend around Q4 and major cold/flu waves.
R&D and regulatory compliance
R&D and regulatory compliance absorb costs for formulation, stability testing and clinical evidence generation, plus filing fees, renewals and multi-jurisdictional audits; pharmacovigilance systems and safety teams run continuous monitoring; IP protection and legal counsel cover patents and enforcement. As of 2024 Haleon is the world’s largest pure-play consumer healthcare company.
- Formulation & trials
- Filing, renewals, audits
- Pharmacovigilance teams
- IP protection & legal
People and technology
People and technology costs center on talent across science, commercial and operations (c.22,000 employees in 2024), incentives and training to drive performance, investments in data platforms, ERP and analytics, plus cybersecurity and privacy safeguards to protect consumer health data.
APIs & packaging ≈60% of COGS; packaging 20–25% pack cost
APIs, excipients and packaging ≈60% of unit COGS; packaging 20–25% of pack cost. 2024 input inflation ~5% y/y; stricter specs added ~2–3% input cost. Plant ops, freight and inventory (20–30% holding p.a.) drive manufacturing overhead. Marketing, trade spend and R&D/regulatory remain material; workforce ≈22,000 in 2024.
| Item | 2024 Metric |
|---|---|
| COGS mix | APIs/excipients/packaging ≈60% |
| Packaging | 20–25% pack cost |
| Input inflation | ~5% y/y |
| Inventory holding | 20–30% p.a. |
| Employees | ≈22,000 |
Revenue Streams
OTC medicines sales
Haleon’s OTC medicines—centered on pain relief and respiratory lines in retail and pharmacy—anchor the business, with the group reporting c.£7.3bn revenue in 2023 and OTC categories forming a large share; premium SKUs carry markedly higher gross margins (around mid‑60s reported for leading brands), seasonal respiratory spikes (often +15–25% in winter quarters) shift SKU mix, and geographic diversity across Americas, Europe and Asia smooths revenue volatility.
Vitamins, minerals, supplements
Everyday vitamins, minerals and supplements deliver frequent, recurring purchase cycles—supporting stable revenue and contributing to the global VMS market valued at about US$161 billion in 2024. Subscription offerings boost predictability and retention, often raising customer lifetime value and smoothing cash flow. Differentiated claims (targeted formulations, clinically-backed benefits) enable premium pricing, while cross-selling with OTC products increases basket size and average order value.
Oral health products
Oral health products—dentifrice, mouthwash and specialized treatments—drive a large share of Haleon’s oral-care sales, with the global oral care market estimated at $48.2bn in 2024 and Haleon’s oral segment ~£2.8bn in 2024; professional endorsements lift penetration, pediatric and sensitivity niches fuel growth, and multi-pack formats increase household reach and repeat purchase rates.
E-commerce and DTC
E-commerce and DTC capture convenience-driven shoppers, enable higher data-driven upsell and product bundling, and typically incur lower trade deductions versus some brick-and-mortar channels; global e-commerce reached about 23% of retail sales in 2024, supporting scale via direct margins and richer customer data.
- Online convenience: higher frequency purchases
- Data-led upsell: personalized bundles
- Lower trade deductions vs retail
- International marketplaces extend reach
Professional and institutional
Professional and institutional revenue stems from direct sales to dental practices, clinics and wholesalers, supported by starter kits and samples tied to clinician education that boost trial and recommendation rates; long-term supply agreements stabilize volumes and margins while clinician influence lifts retail sell-out, contributing to Haleons broader FY 2024 revenue of £7.9bn.
- Sales channels: dental practices, clinics, wholesalers
- Activation: starter kits + samples
- Contracts: long-term agreements
- Impact: clinician influence → retail sell-out
OTC - £7.9bn, mid-60s%, e-comm ≈23%
Haleon’s revenue mix is anchored by OTC medicines within total 2024 group sales of £7.9bn, with premium SKUs showing gross margins around mid‑60s. VMS and oral care offer recurring, high‑frequency purchases (VMS market US$161bn, oral care US$48.2bn in 2024). E‑commerce (≈23% of retail in 2024), subscriptions and professional contracts enhance predictability and reduce channel deductions.
| Metric | Value (2024) |
|---|---|
| Group revenue | £7.9bn |
| OTC premium margin | Mid‑60s % |
| VMS market | US$161bn |
| Oral care market | US$48.2bn |
| E‑commerce share | ≈23% |